• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Immatics N.V.

    6/2/25 4:01:57 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    6-K 1 dp229618_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    June 2, 2025

     

     

     

    Commission File Number: 001-39363

     

    IMMATICS N.V.

     

     

    Paul-Ehrlich-Straße 15

    72076 Tübingen, Federal Republic of Germany

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F

    ☒

      Form 40-F

    ☐

     

     

     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    On June 2, 2025, Immatics N.V. (the “Company”) made available to its shareholders a convening notice to the Company’s annual general meeting. The annual general meeting is expected to take place on June 18, 2025 at 16:00 hours CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands.

     

     

    EXHIBIT INDEX

     

    Exhibit No. Description
    99.1 Convening Notice for the Annual General Meeting
    99.2 Agenda for the Annual General Meeting
    99.3 Proxy Card
    99.4 Form of 2025 Immatics Stock Option & Incentive Plan

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      IMMATICS N.V.
    Date: June 2, 2025  
      By: /s/ Harpreet Singh
      Name: Harpreet Singh
      Title: Chief Executive Officer

     

    Get the next $IMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings

    $IMTX
    SEC Filings

    See more
    • SEC Form 6-K filed by Immatics N.V.

      6-K - Immatics N.V. (0001809196) (Filer)

      6/18/25 1:46:36 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Immatics N.V.

      6-K - Immatics N.V. (0001809196) (Filer)

      6/2/25 4:01:57 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Immatics N.V.

      6-K - Immatics N.V. (0001809196) (Filer)

      6/2/25 7:02:01 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on Immatics N.V. with a new price target

      Deutsche Bank initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $10.00

      5/28/25 9:08:28 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Immatics N.V. with a new price target

      Piper Sandler initiated coverage of Immatics N.V. with a rating of Overweight and set a new price target of $19.00

      10/7/24 7:57:11 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Immatics N.V.

      Cantor Fitzgerald initiated coverage of Immatics N.V. with a rating of Overweight

      11/2/23 7:08:49 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care